aa 214 abiotic stress antigr Glycyrrhiza hormonal treatment kit torrent KRAS mutations medicinal plant mlcard modified oligonucleotides mutation detection
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
The immune system features to defend people towards overseas invaders comparable to micro organism and viruses. Nevertheless, issues of the immune system might result in autoimmunity, inflammatory illness, and most cancers. The inflammatory bowel illnesses (IBD)-Crohn’s illness (CD) and ulcerative colitis (UC)-are persistent illnesses marked by relapsing intestinal irritation.
Though IBD is most prevalent in Western nations (1 in 1,000), incident charges are rising around the globe. By means of affiliation research, researchers have linked a whole bunch of genes to the pathology of IBD. Nevertheless, the frilly pathology behind IBD and the excessive variety of potential genes pose important challenges to find one of the best therapeutic targets.
Moreover, the instruments wanted to functionally characterize every genetic affiliation introduce many rate-limiting elements such because the era of genetically modified mice for every gene. To research the therapeutic potential of goal genes, a mannequin system has been developed utilizing clustered repeatedly interspaced quick palindromic repeats (CRISPR)/CRISPR-associated endonuclease (Cas9)-based applied sciences and a cluster of differentiation 40 (CD40) agonistic antibody.
The current research exhibits that CRISPR/Cas9-mediated modifying within the immune system can be utilized to analyze the affect of genes in vivo. Restricted to the hematopoietic compartment, this strategy reliably edits the ensuing reconstituted immune system. CRISPR/Cas9-edited mice are generated sooner and are far inexpensive than conventional genetically modified mice.
Moreover, CRISPR/Cas9 modifying of mice has important scientific benefits in comparison with producing and breeding genetically modified mice comparable to the flexibility to guage targets which can be embryonic deadly. Utilizing CD40 as a mannequin goal within the CD40 agonistic antibody-induced colitis mannequin, this research demonstrates the feasibility of this strategy.
Twin Web site-Particular Chemoenzymatic Antibody Fragment Conjugation Utilizing CRISPR-Primarily based Hybridoma Engineering
Functionalized antibodies and antibody fragments have discovered purposes within the fields of biomedical imaging, theranostics, and antibody-drug conjugates (ADC). As well as, therapeutic and theranostic approaches profit from the chance to ship multiple kind of cargo to focus on cells, additional difficult stochastic labeling methods.
Thus, bioconjugation strategies to reproducibly acquire outlined homogeneous conjugates bearing a number of totally different cargo molecules, with out compromising goal affinity, are in demand. Right here, we describe a simple CRISPR/Cas9-based technique to quickly engineer hybridoma cells to secrete Fab’ fragments bearing two distinct site-specific labeling motifs, which might be individually modified by two totally different sortase A mutants.
We present that sequential genetic modifying of the heavy chain (HC) and light-weight chain (LC) loci permits the era of a steady cell line that secretes a twin tagged Fab’ molecule (DTFab’), which might be simply remoted. To display feasibility, we functionalized the DTFab’ with two distinct cargos in a site-specific method. This know-how platform shall be useful within the growth of multimodal imaging brokers, theranostics, and next-generation ADCs.
Aptamer-based cell-free detection system to detect goal protein
Biomarkers of illness, particularly protein, present nice potential for prognosis and prognosis. For detecting a sure protein, a binding assay implementing antibodies is usually carried out. Nevertheless, antibodies will not be thermally steady and should trigger false-positive when the pattern composition is sophisticated.
Lately, a practical nucleic acid named aptamer has been utilized in many biochemical evaluation instances, which is usually chosen from random sequence libraries through the use of the systematic evolution of ligands by exponential enrichment (SELEX) strategies. In comparison with antibodies, the aptamer is extra thermal steady, simpler to be modified, conjugated, and amplified.
Herein, an Aptamer-Primarily based Cell-free Detection (ABCD) system was proposed to detect goal protein, utilizing epithelial cell adhesion molecule (EpCAM) for example. We mixed the robustness of aptamer in binding specificity with the sign amplification capability of CRISPR-Cas12a’s trans-cleavage exercise within the ABCD system.
We additionally demonstrated that the ABCD system might work properly to detect goal protein in a comparatively low restrict of detection (50-100 nM), which lay a basis for the event of moveable detection gadgets. This work highlights the prevalence of the ABCD system in detecting goal protein with low abundance and provides new enlightenment for future design and growth.
A value environment friendly protocol to introduce epitope tags by CRISPR-Cas9 mediated gene knock-in with uneven semi-double stranded template
To review the organic perform of uncharacterized proteins, particular antibodies are in excessive demand. Nevertheless, the manufacturing of fascinating antibodies comparable to extremely particular or excessive affinity isn’t all the time profitable.
Moreover, even when commercially accessible antibodies exist, the fee, high quality, and accessibility usually differ from nation to nation. Compared, epitope tags are dependable and economical choices since good antibodies towards main epitope tags are commercially accessible. Though exogenously expressed epitope-tagged protein seems as a well timed methodology, the extreme protein manufacturing might not faithfully recapitulate its biology.
Because of the latest advances in genome modifying by CRISPR-Cas9, HDR-mediated endogenous protein tagging has grow to be an accessible strategy for a lot of labs. Nevertheless, presently the synthesis of lengthy (>100 bp), chemically modified oligos might be time-consuming and dear. To develop a dependable, easy, and cost-effective epitope-tagging methodology that requires minimal supplies and equipment, we deal with an strategy using two non-chemically modified shorter-annealed oligos (semi-dsODNs) mediated HDR for epitope tags insertion.
We additionally use a cationic lipid chemical, polyethyleneimine (PEI), for plasmid supply to attenuate the fee and supplies used whereas a substantial success price may very well be achieved. This protocol supplies a extra economical option to generate CRISPR-Cas9 mediated gene knock-in.
This protocol supplies a simplified design of semi-dsODN with out chemical modification on the oligos. This protocol supplies a simplified experimental process. In vitro assembled Cas9 complicated and electroporation will not be required.
CRISPR/Cas12a-powered immunosensor appropriate for ultra-sensitive complete Cryptosporidium oocyst detection from water samples utilizing a plate reader
Waterborne pathogens, comparable to Cryptosporidium parvum, pose a significant risk to public well being globally, and this requires screening of ingesting and environmental water for low variety of contaminating microbes. Nevertheless, present detection approaches usually require skilled specialists with refined devices, and will not be appropriate for large-scale screening and speedy outbreak response.
Latest advances in ultrasensitive CRISPR/Cas-based biosensing proceed to increase the vary of detectable molecular targets, nonetheless single microbes couldn’t be immediately detected up to now, particularly in environmental samples. Right here, we report an ultrasensitive CRISPR/Cas12a-powered immunosensing methodology appropriate for microbial detection which hyperlinks antibody-based recognition with CRISPR/Cas12a-based fluorescent sign amplification by an antibody-DNA conjugate.
This strategy is proven right here to detect complete four µm measurement Cryptosporidium parvum oocysts with a linear vary from 6.25 – 1600 oocysts/mL, at a most sensitivity of single oocyst per pattern. Its potential to use to varied complicated pattern matrices has additionally been demonstrated. After pattern dilution by issue of 10, we had been capable of detect 10 oocysts from a back-wash mud samples from water therapy plate.
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000-050 | EpiGentek | 50 ug | EUR 200.2 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000-100 | EpiGentek | 100 ug | EUR 355.3 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000 | EpiGentek |
|
|
CRISPR-Cas9 SP recombinant monoclonal antibody |
|||
| A5899 | Bimake | 100ul X 3 | EUR 714 |
|
Description: A recombinant monoclonal antibody from rabbit against human CRISPR-Cas9 SP for WB,ELISA |
|||
Anti-CRISPR-Cas9 Rabbit Monoclonal Antibody |
|||
| M30929-1 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Rabbit Monoclonal CRISPR-Cas9 Antibody. Validated in IP, IF, WB and tested in Streptococcus pyogenes. |
|||
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
| A-9001-010 | EpiGentek | 10 ug | EUR 70.4 |
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
| A-9001-050 | EpiGentek | 50 ug | EUR 192.5 |
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
| A-9001-100 | EpiGentek | 100 ug | EUR 338.8 |
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
| A-9001 | EpiGentek |
|
|
CRISPR-Associated Endonuclease Cas9/Csn1 (Cas9) Antibody |
|||
| abx340123-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-CRISPR-Cas9 SP Rabbit Monoclonal Antibody |
|||
| M30929 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Rabbit Monoclonal CRISPR-Cas9 SP Antibody. Validated in IF, WB and tested in Streptococcus pyogenes. |
|||
CRISPR / hCas9 Adenovirus |
|||
| AVP010 | GenTarget | 1x109 IFU/ml x 200ul | EUR 541.2 |
|
Description: pre-made adenovirus expresses the neclear penetrated, human codon optimized wild-type Cas9 endonuclease, provided in DMEM medium. |
|||
Scrambled sgRNA CRISPR Lentivector |
|||
| K018 | ABM | 1.0 ug | EUR 184.8 |
CRISPR sgRNA Synthesis Kit |
|||
| K1251-25 | Biovision | each | EUR 483.6 |
TDOR sgRNA CRISPR Lentivector set () |
|||
| K9000801 | ABM | 3 x 1.0 ug | EUR 406.8 |
CRISPR Genomic Cleavage Detection Kit |
|||
| G932 | ABM | 25 Reactions | EUR 246 |
Classic CRISPR sgRNA Synthesis Kit |
|||
| K1252-25 | Biovision | 25 Reactions | EUR 526.8 |
|
Description: Classic CRISPR sgRNA Synthesis Kit |
|||
CRISPR Genomic Cleavage Detection Kit |
|||
| K1250-25 | Biovision | each | EUR 483.6 |
Express CRISPR sgRNA Synthesis Kit |
|||
| K1253-25 | Biovision | each | EUR 639.6 |
LAG3 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78053 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T-cells, Natural Killer cells, B-cells, and plasmacytoid dendritic cells. Its main ligand is the MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T-cells in a similar fashion as CTLA-4 and PD-1, and has been reported to play a role in T-reg suppressive function. A number of LAG3 antibodies are in preclinical development for the treatment of cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1, because antibodies targeting CTLA-4 or PD-1 only activate effector T-cells while failing to inhibit T-reg activity, whereas an antagonist LAG3 antibody can both activate effector T-cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) T-reg suppressive activity. The LAG3 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human LAG3 (GenBank Accession #NM_002286) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ _x000D_ |
|||
CTLA4 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78054 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: CTLA4 (Cytotoxic T-Lymphocyte Associated Protein), also known as CD152, is a protein receptor that functions as an immune checkpoint. It is expressed by activated T-cells and transmits an inhibitory signal to T-cells. CTLA4 is homologous to the T-cell co-stimulatory protein CD28, and both molecules bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA4 binds CD80 and CD86 with greater affinity and avidity than CD28, thus enabling it to out-compete CD28 for its ligands and act as an "off" switch when bound to CD80 or CD86. CTLA4 is an important immunotherapy target for the treatment of cancer and autoimmune diseases._x000D_ The CTLA4 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human CTLA4, GenBank Accession #NM_005214, driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
TCR CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78055 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: The T-Cell Receptor (TCR) is found on the surface of T-cells and is responsible for recognizing antigens bound to MHC (Major Histocompatibility Complex) molecules. Activation of the TCR results in activation of downstream NFAT signaling. The TCR consists of a heterodimer of two different protein chains, of which the alpha (α) and beta (β) chains are the predominant chains._x000D_ The TCR CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TRAC (T-Cell Receptor Alpha Constant) and human TRBC1 (T-Cell Receptor Beta Constant 1) regions of the α and β chains._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
CD47 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78056 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: CD47 (also known as Rh-associated protein, GP42, Integrin-Associated Protein (IAP), or Neurophilin) is an immunoglobulin-like protein that interacts with its receptor, Signal-regulatory protein alpha (SIRPα), on macrophages. This binding interaction regulates transmigration, oxidative burst cytokine production, and phagocytosis, generating a "don't eat me" signal. CD47 is ubiquitously expressed on the surface of normal cells, but is overexpressed in numerous cancer cells where it is thought to contribute to the resistance of tumors to phagocyte-dependent clearance._x000D_The CD47 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human CD47 (NM_198793.2) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
TIGIT CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78058 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: TIGIT (T-cell immunoreceptor with Ig and ITIM domains; VSTM3; VSIG9) is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells and activated CD4+, CD8+, and regulatory T-cells. Interaction with the Poliovirus Receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits either the Src homology (SH) domain-containing tyrosine phosphatases SHP1 and SHP2, or the Inositol phosphatase SHIP1 and SHIP2, to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-κB and NFAT T-cell receptor (TCR) signaling, which blocks T-cell proliferation and cytokine production. TIGIT also serves as a competitive inhibitor of CD226, a costimulatory receptor for CD155. TIGIT-targeting antibodies which block this T-cell intrinsic inhibitory effect have shown enhanced anti-tumor and anti-viral functions in preclinical studies._x000D_ The TIGIT CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TIGIT (GenBank Accession #NM_173799) driven by a U6 promoter._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest. |
|||
CRBN CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78517 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Cereblon (CRBN) forms an E3 ubiquitin ligase complex which is responsible for ubiquitinating proteins that regulate various developmental processes. CRBN also binds to Calcium Activated Potassium Channel subunit alpha-1 (KCNMA1) to regulate ion transport. Moreover, mutations in CRBN may play an underlying role in tumor cells acquiring resistance to immunotherapy.The CRBN CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human CRBN.The DNA transduced by this lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type. |
|||
TGFBR2 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78535 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Transforming growth factor receptor beta 2 (TGFBR2) encodes the TGF-β receptor protein, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGF-β. This receptor/ligand complex phosphorylates proteins which regulate cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Mutations in TGFBR2 have been linked with Marfan syndrome and the development of various types of tumors.The TGFBR2 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human TGFBR2.The DNA transduced by this lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiency is dependent on cell type. |
|||
FCGR2A CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78537 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Fc Gamma Receptor 2A (also known as CD32A, Fc-gamma-RIIa, FcgRIIa) is a low affinity Fc receptor for immunoglobulin G, encoded by the FCGR2A gene. Fc Gamma Receptor 2A is a cell surface receptor that is expressed on a variety of immune cells such as macrophages and neutrophils. It is involved in phagocytosis and in the clearing of spent immune complexes from the circulation. A polymorphism in FCGR2A has been associated with increased risks of nephritis and lupus.The FCGR2A CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to transduce into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human FCGR2A. |
|||
NLRP3 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78545 | BPS Bioscience | 500 µl x 2 | EUR 995 |
|
Description: NLR family Pyrin domain containing 3 (NLRP3) is expressed in macrophages and is a component of inflammasomes. NLRP3 detects uric acid and extracellular ATP in damaged tissue and interacts with a pro-apoptotic protein that recruits caspases. This complex is also an upstream activator of NF-κB signaling and triggers an immune response as part of the innate immune system. Mutations in NLRP3 are known to cause autoinflammatory and neuroinflammatory diseases, such as Alzheimer's, Parkinson's, and prion disease. The NLRP3 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human NLRP3 (Figure 1 and Table 1), allowing the knockdown of NLRP3 in transduced cells.The DNA transduced by the integrating lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiencies also depend on the cell type. |
|||
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | each | Ask for price |
CRISPR / hCas9 Adenovirus, in vivo ready |
|||
| AVP010-PBS | GenTarget | 1x1011 IFU/ml x 50ul | EUR 852 |
|
Description: pre-made adenovirus expresses the neclear penetrated, human codon optimized wild-type Cas9 endonuclease, provided in PBS solution. |
|||
ARL16 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123301 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARL17 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123401 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARL17P1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123501 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123601 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC2 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123701 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC3 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123801 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC4 sgRNA CRISPR Lentivector set (Human) |
|||
| K0123901 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC5 sgRNA CRISPR Lentivector set (Human) |
|||
| K0124001 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARMC6 sgRNA CRISPR Lentivector set (Human) |
|||
| K0124101 | ABM | 3 x 1.0 ug | EUR 406.8 |
This methodology makes use of the identical experimental setup (plate reader) as a traditional ELISA assay thus lowering the necessity for microscopy-based identification of Cryptosporidium, which represents the gold-standard however requires excessive degree experience and time-consuming guide counting. This work highlights the potential of CRISPR/Cas-based biosensing for water high quality evaluation and ultrasensitive complete pathogen detection.
